Redeye comments on Fable Media Group’s Q3 results, which came in somewhat lower than expected in ter...
Redeye comments on Raketech’s Q3-results which were weaker than expected, driven mainly by Sub-affil...
Signs SEK 132m expansion order from Swedish Space Corporation New run-rate of ~SEK 250m is 37% above...
I dag offentliggjorde Angler Gaming sin delårsrapport för Kv3 2024.
Redeye comments on Embracer’s Q2-results which were somewhat weaker than expected, owing mainly to P...
Redeye provides its initial take on Surgical Science’s Q3 2024 report, which beat our expectations.
Redeye is encouraged by the new management in Sivers, guiding for a long-term ambition of reaching a...
Stigande affärsaktivitet Bolaget rapporterade en minskning av nettoomsättningen under det tredje kva...
Redeye updates on Gentoo Media following Q3-results where we have made limited changes to estimates ...
Redeye somewhat cuts its forecasts and Base Case following a Q3 with soft ARR growth yet lower OPEX ...
Redeye provides an update on Scandinavian ChemoTech following the Q3 2024 report.
Nettoomsättningen uppgick till 204,8 MSEK (193,3), vilket motsvarade en ökning med 6,0 procent y-o-y...
Irisity AB (”Irisity” or ”the Company”) is a leading provider of AI-driven video analytics solutions...
Redeye is favourable to InfraCom’s Q3 2024 report, which resulted in the stock rallying 9%, although...
Nu är guldproduktionen i Fäbodtjärn i gång. Gruvan invigdes i maj och i augusti sköts den första mal...
Redeye comments on Gentoo Media’s Q3-results which were in line with the preliminary results announc...
Redeye comments on yesterday’s news that Kancera will concentrate its resources on cardiovascular di...
Redeye has updated its estimates and valuation following Physitrack’s Q3 report.
Redeye views the Q3 report as relatively uneventful, apart from the apparent successful launch of Te...
Redeye updates on EG7 post Q3-results which were better than expected, driven by strong profitabilit...
